All News

"Continuing certification is not merely a bureaucratic process; it is a commitment to staying abreast of advancements in urology and maintaining competencies," writes J. Stuart Wolf Jr, MD, FACS.

The real-world study plans to enroll 500 patients who are utilizing the Leva Pelvic Health System, a non-invasive medical device to help women train and strengthen pelvic floor muscles.

The investigators at DSUI developed 4 recommended actions for urologists based on the findings from the survey: drive multidisciplinary collaboration, leverage technology excellence, bridge patient-urologist perspectives, and foster collaboration with general practitioners.

The goals of the American Urogynecologic Society (AUGS) program are to support novel clinical, translational, and bench research pilot projects and enable early career investigators to obtain future independent funding for research.

The approval is based on results from the phase 3 THOR trial.

Overall, more than 78% of consumers were able to appropriately self-select to use avanafil using the drug facts label (DFL) and the assistive app, compared with 56% of consumers using the DFL alone.

Validation testing suggested the combined model would prevent unnecessary systematic prostate biopsies in over 40% of study patients.

"Creating a year-to-year plan can ensure you are staying on track to accomplish your short-term and long-term goals," writes Jeff Witz, CFP.

There are several new CPT codes for 2024, including Category III codes for tibial nerve stimulation and other changes to codes in the treatment of urinary incontinence.

"In deciding whom to discharge within hours of a less invasive but major surgery, we must ask ourselves which master we are serving: the insurer, the administrator, or our own ego," writes Badar M. Mian, MD.

A phase 3 study is expected to initiate in 2024 to explore the safety and efficacy of UGN-103 in LG-IR-NMIBC.

The mHealth mobile app provides patients with incremental education on post-cystectomy recovery, delivering information at various timepoints after the patient is discharged from the hospital.

“These [patient-reported outcome] data are supportive of the use of [enfortumab vedotin plus pembrolizumab] as a 1L therapy option for patients who are cisplatin-ineligible," write the authors.

NRX-101 is a fixed-dose combination of the broad-spectrum antibiotic D-cycloserine and lurasidone.

Nadofaragene firadenovec received FDA approval in December 2022 for the treatment of patients with high-risk BCG-unresponsive NMIBC with carcinoma in situ with or without papillary tumors.

From a show dog to a family of cats, let's see who some of the top medical professionals are spending their time with when they're not in the clinic.

"Without interoperability, electronic insurance billing would be nearly impossible. Insurance payers, healthcare providers and claim clearinghouses all rely on interoperability at their core," writes Lisa Taylor.

Clarius Bladder AI ultrasound software may have significant utility in acute care settings, urology clinics, and nursing homes.

In total, the study plans to enroll approximately 100 BCG-unresponsive NMIBC CIS patients across 15 clinical study sites in the US and Canada.

The conference, “PSMA PET and RLT: Present and Future," is taking place online and in-person in San Francisco on January 18 and 19, 2024.

"Specialty providers can take three steps now to succeed with MIPS while prioritizing caring for their patients," writes Wayne Singer.

"While preliminary in nature, these data provide a compelling rationale for consideration of PSMA PET as an alternative staging modality at the time of primary diagnosis," wrote the authors.

“To our knowledge, this is the largest investigation of the antitumor effect and toxicity of 225Ac-PSMA radioligand therapy in mCRPC,” the authors wrote.

Neeraj Agarwal, MD, discusses an analysis from the phase 3 TITAN trial that explored the correlation between PSA response and survival among patients with metastatic castration-sensitive prostate cancer receiving apalutamide.

"While alkaline water products have a higher pH than regular water, they have a negligible alkali content–which suggests that they can't raise urine pH enough to affect the development of kidney and other urinary stones," says Roshan M. Patel, MD.

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

The phase 1/2 study is scheduled to commence in the first half of 2024.

"The mental toll of excessive screen time is a pressing concern in health care," writes Neil Baum, MD.